Okay folks, I am no sure whether to laugh of cry - or maybe get really
scared.

Jake Marcus-Cipolla





  FRAMINGHAM, Mass., Nov. 6 /PRNewswire/ -- Genzyme Transgenics Corp.
(Nasdaq:GZTC) today announced that it has achieved expression levels of
3 milligrams per milliliter of human prolactin in the milk of transgenic
mice,
a level 30 to 50 times greater than that achieved in conventional cell
culture
production systems.
          Because of the high expression levels in mice, the company believes
that
transgenic production of prolactin will be potentially more cost-effective
than traditional methods of producing the protein.
          Genzyme Transgenics has also demonstrated that transgenically
produced
prolactin is biologically active, and has already begun work toward producing
prolactin in the milk of transgenic goats.
          The company is developing prolactin as part of its "nutraceuticals"
program.  Nutraceuticals, a growing segment of the health care products
market, are nutritional supplements that have dietary and health benefits.
Genzyme Transgenics believes that the development time for nutraceuticals may
be shorter than for traditional pharmaceuticals because nutritional
supplements are often not required to undergo extensive clinical trials prior
to product launch.
          Human prolactin, a protein secreted by several body tissues,
including the
pituitary and mammary glands and cells of the immune system, may enhance the
body's immune defenses against disease.
          Prolactin affects a broad spectrum of immune cells which may, in
turn,
improve immunity.  Preclinical studies have demonstrated that prolactin
increases antibody levels in response to vaccination and enhances the ability
of immune cells to kill bacteria.  In addition, the studies show that
prolactin increases white blood cell production of interleukin-2 and gamma
interferon - two important immune cell growth factors involved in immune
responses.  The studies also show that prolactin increases the proliferation
of antigen-specific white blood cells and the ability of certain types of
white blood cells to kill bacteria.
          Prolactin is secreted into milk during lactation and has several
apparent
beneficial effects on the development of newborn babies.  Scientists believe
it contributes to immune system maturation, the development of active
substances on the surfaces of the gut and lung, and active immunity against
infections.  Given prolactin's immunity-enhancing effects, high prolactin
levels may help protect infants from infections in the first year of life,
during which time the immunity they gained passively from their mothers
diminishes.
          Genzyme General (Nasdaq:GENZ), which holds exclusive rights to
recombinant human prolactin and certain uses, has licensed rights to Genzyme
Transgenics in the nutritional field.
          Genzyme Transgenics is a biotechnology company focused on
biopharmaceutical development through transgenic production of genetically
engineered therapeutic products; specialized contract research services for
pharmaceutical, biotechnology, medical device, and other companies; and the
production of cancer vaccines.  Genzyme General owns approximately 43 percent
of the outstanding stock of Genzyme Transgenics.
          This press release contains forward-looking statements about the
cost-
effectiveness of transgenically produced recombinant human prolactin and the
development time for nutraceutical products.  Actual results may differ
materially from these projections depending on the price-sensitivity of
customers, the accuracy of the company's information about potential
competitors, and the content and timing of decisions of regulatory agencies
worldwide.
          Genzyme Transgenics' releases are on the World Wide Web at
http://www.genzyme.com.  They are also available from Genzyme's fax-on-demand
service at 1-800-436-1443 within the United States or 1-201-521-1080 outside
the United States.